Home
Conferences
All Conferences
ESMO 2026
GBCC 2026
SABCS 2025
GBCC 2025
SABCS 2024
SABCS 2023
Add Your Conference
Register
Log in
2026 Video Highlights - Starts Now
Supported by An Educational Grants From Stemline/Menarini and Gilead
New Videos Released Daily!
View Session
4092659
ESMO 2026: ADCs in Metastatic HR+ HER2 BC: Clinical Evidence and Future Directions
Virginia Kaklamani, MD, DSc
4:00 Minutes
1:00 PM-
View Session
4158537
ESMO 2026: A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA
Elisabetta Munzone, MD
6:00 Minutes
1:30 PM-
View Session
4158536
ESMO 2026: Residual Cancer Burden (RCB) Following Neoadjuvant Treatment (NAT) with T-DXd→THP vs Dose-Dense Doxorubicin + Cyclophosphamide→THP (ddAC-THP) in High-Risk HER2+ Early-Stage Breast Cancer (eBC)
Lajos Pusztai, MD, DPhil
2:40 Minutes
1:30 PM-
View Session
4092657
ESMO 2026: Lifestyle and Breast Cancer: What the Evidence Tells Us
Neil Iyengar, MD
10:00 Minutes
1:30 PM-
View Session
4173587
ESMO 2026: First-line (1L) Datopotamb Deructecan (Dato-DXd) vs Chemotherapy (CT) in Patients with Locally Recurrent Inoperable or (mTNBC) for Whom Immunotherapy was Not an Option: Patient-Reported Outcomes (PROs) from TROPION-Breast02
Janice Tsang, MD
5:15 Minutes
3:30 PM-
View Session
4172626
ESMO 2026: From Clinical Criteria to Actionable Biomarkers. Guiding Neoadjuvant and Adjuvant.
Nadia Harbeck, MD, PhD
4:00 Minutes
3:30 PM-
View Session
4158539
ESMO 2026: 5-year Invasive Disease-Free Survival (iDFS) of the Strategy Based, Randomized Phase II PHERGain Trial Evaluating Chemotherapy (CT) De-Escalation in HER2(+) Early Breast Cancer (EBC) Patients (pts)
Matteo Lambertini, MD, PhD
3:00 Minutes
3:30 PM-
View Session
4158540
ESMO 2026: Risk Reducing Surgery and Survival in BRCA Mutation Carriers
Matteo Lambertini, MD, PhD
5:15 Minutes
3:30 PM-
View Session
4173582
ESMO 2026: Safety and (PROs) from evERA Breast Cancer: A phase III trial of (GIRE) + everolimus (E) in pts with oestrogen receptor-positive, HER2-negative advanced breast cancer(ER+, HER2,-aBC) previously treated with a CDK4/6 inhibitor (i)
Janice Tsang, MD
5:15 Minutes
3:30 PM-
View Session
4172628
ESMO 2026: Evolving Standards in 2L ER+ HER2+ MBC
Nadia Harbeck, MD, PhD
4:00 Minutes
3:30 PM-
© 2026 Encore Medical Education. All Rights Reserved.
Terms & Conditions
Privacy Policy
Copy to Clipboard
